Form 4: Kiniksa Pharmaceuticals Executive Awarded Performance-Based Share Units and Options

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, received performance share units and options tied to the progress of KPL-387, a treatment for recurrent pericarditis.

Summary

• On May 1, 2025, Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, was granted performance share units (PSUs) and performance share options.
• The PSUs and options are contingent upon the achievement of specific performance criteria related to KPL-387, a treatment for recurrent pericarditis.
• 4,975 PSUs will vest upon submission of a biologics license application to the FDA, while 5,224 PSUs will vest upon FDA approval for commercial sale and marketing of KPL-387.
• 8,042 performance share options will vest upon submission of a biologics license application to the FDA, while 8,302 performance share options will vest upon FDA approval for commercial sale and marketing of KPL-387.
• The vesting of these awards is also subject to Tessari's continued employment with the company, with certain exceptions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of performance-based awards suggests confidence in the company's ability to achieve its goals, particularly regarding KPL-387. However, the value is contingent on future success.

Positives

• The performance-based awards align executive compensation with the successful development and commercialization of KPL-387.
• Achievement of FDA milestones could lead to significant value creation for the company and its shareholders.
• The vesting conditions incentivize continued employment and commitment from the COO.

Risks

• Failure to achieve the performance criteria (FDA submission and approval) will result in the forfeiture of the PSUs and options.
• Tessari's departure from the company could also impact the vesting of the awards.

Future Outlook

The future value of the PSUs and options is dependent on the successful development, regulatory approval, and commercialization of KPL-387.

Industry Context

Biopharmaceutical companies often use performance-based equity awards to incentivize executives to achieve key clinical and regulatory milestones. The focus on FDA approval reflects the critical importance of regulatory success in the pharmaceutical industry.

Comparison to Industry Standards

• Many pharmaceutical companies use performance-based equity compensation to align executive incentives with drug development milestones.
• Companies like Amgen, Regeneron, and Biogen also utilize similar compensation structures tied to clinical trial results and regulatory approvals.
• The specific terms of the awards, such as the vesting conditions and performance criteria, are tailored to the company's specific goals and circumstances.

Stakeholder Impact

• Shareholders: Successful development and commercialization of KPL-387 could lead to increased shareholder value.
• Employees: Achievement of the performance criteria could result in increased job security and potential for further compensation.
• Patients: Successful development of KPL-387 could provide a new treatment option for recurrent pericarditis.

Next Steps

• Kiniksa will need to achieve the performance criteria related to KPL-387, including submission of a biologics license application to the FDA and obtaining FDA approval.
• The company will also need to ensure Tessari's continued employment to maintain the vesting of the awards.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Eben Tessari, Performance Share Units, Performance Share Options, KPL-387, FDA, Recurrent Pericarditis, Executive Compensation, Vesting